1. Ciemins, Elizabeth L. PhD
  2. McKinnon, Monette
  3. Hamersky, Carol Mahler PhD
  4. Iyer, Neeraj N. PhD
  5. Powelson, Jill DrPH


Guidelines for the management of patients with type 2 diabetes mellitus (T2DM) recommend SGLT-2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 RAs (glucagon-like peptide 1 receptor agonists) as second-line agents for patients with, or at risk for, cardiovascular disease. A better understanding of guideline implementation will further the provision of evidence-based health care to patients. Interviews and surveys of clinicians were conducted to understand providers' knowledge, attitudes, and beliefs related to the 2019 American Diabetes Association Standards of Care for T2DM. There was a lack of widespread knowledge of the guidelines and comfort with their use. Clinicians require additional training and education on the efficacy of the new medications and accompanying clinical guidelines.